Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson’s disease
J Neural Transm. 2019-05-16; 126(6): 789-793
DOI: 10.1007/s00702-019-02015-x
Lire sur PubMed
1. J Neural Transm (Vienna). 2019 Jun;126(6):789-793. doi:
10.1007/s00702-019-02015-x. Epub 2019 May 16.
Delamarre A(1)(2)(3), Tison F(1)(2)(3), Li Q(4)(5), Galitzky M(6), Rascol O(6)(7)(8), Bezard E(1)(2)(3)(4)(5), Meissner WG(9)(10)(11)(12)(13).
Author information:
(1)Service de Neurologie, Hôpital Pellegrin, CHU de Bordeaux, 33000, Bordeaux, France.
(2)Institut des Maladies Neurodégénératives, Université de Bordeaux, UMR 5293, 146 rue Léo Saignat, 33000, Bordeaux Cedex, France.
(3)CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France.
(4)Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China.
(5)Motac Neuroscience, Manchester, UK.
(6)CIC Toulouse, Toulouse, France.
(7)Départements de Pharmacologie Clinique et Neurosciences, INSERM CIC9302, CHU de Toulouse, Toulouse, France.
(8)Service de Pharmacologie, Faculté de Médecine, CHU de Toulouse, Université de Toulouse, Toulouse, France.
(9)Service de Neurologie, Hôpital Pellegrin, CHU de Bordeaux, 33000, Bordeaux, France. .
(10)Institut des Maladies Neurodégénératives, Université de Bordeaux, UMR 5293, 146 rue Léo Saignat, 33000, Bordeaux Cedex, France. .
(11)CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France. .
(12)Department Medicine, University of Otago, Christchurch, New Zealand. .
(13)New Zealand Brain Research Institute, Christchurch, New Zealand. .
We tested in a translational approach the usefulness of plasma creatine kinase (CK) as an objective biomarker for levodopa-induced dyskinesia (LID). Plasma CK levels were measured in five dyskinetic parkinsonian non-human primates (NHP) and in ten PD patients with LID who participated in a treatment trial with simvastatin. Plasma CK levels were increased in dyskinetic NHP and correlated with LID severity while they were not affected by LID severity in PD patients.
DOI: 10.1007/s00702-019-02015-x
PMID: 31098725